Synthesis, molecular modelling and CYP24A1 inhibitory activity of novel of (E)-N-(2-(1H-imidazol-1-yl)-2-(phenylethyl)-3/4-styrylbenzamides
-
Add time:07/13/2019 Source:sciencedirect.com
CYP24A1 (25-hydroxyvitamin D-24-hydroxylase) is a useful enzyme target for a range of medical conditions including cancer, cardiovascular and autoimmune disease, which show elevated CYP24A1 levels and corresponding reduction of calcitriol (the biologically active form of vitamin D). A series of (E)-N-(2-(1H-imidazol-1-yl)-2-(phenylethyl)-3/4-styrylbenzamides have been synthesised using an efficient synthetic route and shown to be potent inhibitors of CYP24A1 (IC50 0.11–0.35 μM) compared with the standard ketoconazole. Molecular modelling using our CYP24A1 homology model showed the inhibitors to fill the hydrophobic binding site, forming key transition metal interaction between the imidazole nitrogen and the haem Fe3+ and multiple interactions with the active site amino acid residues.
We also recommend Trading Suppliers and Manufacturers of Benzamide, 4-ethyl-N-(1-phenylethyl)- (cas 116368-37-7). Pls Click Website Link as below: cas 116368-37-7 suppliers
Prev:Synthesis and pharmacological evaluation of benzamide derivatives as potent and selective sigma-1 protein ligands
Next:Synthesis and CYP24A1 inhibitory activity of N-(2-(1H-imidazol-1-yl)-2-phenylethyl)arylamides) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Discovery, structure-activity relationship studies, and anti-nociceptive effects of N-(1,2,3,4-tetrahydro-1-isoquinolinylmethyl)benzamides as novel opioid receptor agonists07/17/2019
- Discovery of 3-(4-methanesulfonylphenoxy)-N-[1-(2-methoxy-ethoxymethyl)-1H-pyrazol-3-yl]-5-(3-methylpyridin-2-yl)-benzamide as a novel glucokinase activator (GKA) for the treatment of type 2 diabetes mellitus07/16/2019
- “One-pot” sequential preparation of isoquinoline-1,3(2H,4H)-dione derivatives by reacting N-alkyl(aryl)-N-methacryloyl benzamides with benzyl alcohols and sodium benzenesulfinates07/15/2019
- Synthesis and CYP24A1 inhibitory activity of N-(2-(1H-imidazol-1-yl)-2-phenylethyl)arylamides07/14/2019
- Synthesis and pharmacological evaluation of benzamide derivatives as potent and selective sigma-1 protein ligands07/12/2019
- Microbial deracemisation of N-(1-hydroxy-1-phenylethyl)benzamide07/11/2019


